Assetmark Inc. Significantly Boosts DexCom Stake

Hedge fund increases position in medical device company by over 10,000%

Apr. 18, 2026 at 7:23am

Got story updates? Submit your updates here. ›

An extreme close-up of the complex internal mechanisms and sensors of a continuous glucose monitoring device, rendered in a high-contrast, industrial style that emphasizes the precision engineering and advanced technology behind DexCom's products.Assetmark Inc.'s major investment in DexCom signals growing Wall Street confidence in the medical device company's innovative glucose monitoring technology.San Diego Today

Assetmark Inc., a financial services firm, has dramatically increased its stake in DexCom, Inc. (NASDAQ:DXCM), a leading medical device company that develops continuous glucose monitoring systems. According to a recent 13F filing, Assetmark grew its DexCom holdings by over 10,400% in the fourth quarter, now owning 143,618 shares worth $9.5 million.

Why it matters

This significant increase in Assetmark's DexCom position suggests the hedge fund sees strong growth potential in the medical device company, which has been a leader in the continuous glucose monitoring market. The move also highlights increased investor interest in DexCom as the company continues to innovate and expand its product offerings for diabetes management.

The details

Assetmark Inc. acquired an additional 142,256 shares of DexCom in the fourth quarter, bringing its total position to 143,618 shares. This represents a staggering 10,444.6% increase in the firm's DexCom holdings compared to the prior quarter. DexCom is a medical technology company that develops and distributes continuous glucose monitoring (CGM) systems for people with diabetes.

  • Assetmark Inc. increased its DexCom stake in the fourth quarter of 2025.

The players

Assetmark Inc.

A financial services firm that significantly increased its stake in DexCom, Inc. in the fourth quarter.

DexCom, Inc.

A medical device company that develops and distributes continuous glucose monitoring systems for people with diabetes.

Got photos? Submit your photos here. ›

The takeaway

Assetmark's dramatic increase in its DexCom position underscores the growing investor interest in the medical device company as it continues to innovate and expand its footprint in the diabetes management market. This move suggests Assetmark sees significant long-term growth potential in DexCom.